CRDL (Cardiol Therapeutics) Change In Receivables : $-0.06 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cardiol Therapeutics Change In Receivables?

Cardiol Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was $-0.07 Mil. It means Cardiol Therapeutics's Accounts Receivable increased by $0.07 Mil from Sep. 2024 to Dec. 2024 .

Cardiol Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $-0.06 Mil. It means Cardiol Therapeutics's Accounts Receivable increased by $0.06 Mil from Dec. 2023 to Dec. 2024 .

Cardiol Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cardiol Therapeutics's liquidation value for the three months ended in Dec. 2024 was $16.51 Mil.

Cardiol Therapeutics Change In Receivables Historical Data

The historical data trend for Cardiol Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Change In Receivables Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

0.55

-0.15

-0.05

0.15

-0.06

Cardiol Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															0.01	-0.03	0.06	-0.02	-0.07

Cardiol Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Cardiol Therapeutics (NAS:CRDL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cardiol Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.07	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cardiol Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cardiol Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	21.464	-	5.008	+	0.75 * 0.07	+	0.5 * 0
=	16.51

Cardiol Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (NAS:CRDL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CT9:Germany CRDL:Canada

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.